Tag Archive for: CEO

NeoPhore appoints Michael Shih as Chief Executive Officer

Highly experienced corporate development leader with a track record of international pharma and biotech deal-making New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer London UK, 16 December 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as Chief Executive […]

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025

David Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical Officer James Sabry, ex-Head of Pharma Partnering at Roche, joins the Board as Vice-Chair [28 October 2024]: [London, UK/ Boston, US]: Ottimo Pharma, […]

AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team

Jane Rhodes appointed as Chief Executive Officer Magnus Ivarsson appointed as Chief Translation and Early Development Officer London UK, 1 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA, as Chief Executive Officer (CEO) and member […]

Gareth Williams appointed CEO of Bionical Health

Willington, UK, June 19, 2024 – Bionical Solutions, a leading provider of technology enabled engagement and healthcare services to global pharmaceutical, biotech, healthcare companies and the NHS, today announces the appointment of Gareth Williams as CEO of Bionical Health Ltd. Gareth has an exemplary track record, spanning over 20 years, helping build organisations which have a […]

Interim Management Statement on the First Three Months of 2024

First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further development of the ADC pipeline Ladenburg, Germany, 25 April 2024 – Heidelberg Pharma AG (FSE: HPHA) today reported on the […]